Azitra Inc (AZTR) AI Stock Analysis

• Market Cap: $3.26M
• Dividend Yield: N/A
• Average Volume (3M): 169.78K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.14
• Revenue Growth: -100.00%
• EPS Growth: 93.82%
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.67
• Shares Outstanding: 10,740,697
• 10 Day Avg. Volume: 152,326
• 30 Day Avg. Volume: 169,784
• PEG Ratio: <0.01
• Price to Book (P/B): 0.28
• Price to Sales (P/S): 0.21
• P/FCF Ratio: -0.16
• Enterprise Value/Market Cap: 1.16
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -11.19
• Enterprise Value/Ebitda: -0.37
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $0.37 ▲(22.00% Upside)

Azitra Inc's overall stock score is primarily impacted by its financial performance, characterized by strong revenue growth but overshadowed by high losses and negative cash flows. The technical analysis indicates a bearish trend, and the valuation is weak due to a negative P/E ratio. The compliance notice from NYSE adds further risk.

Positive Factors

Revenue Growth

The substantial increase in revenue indicates a positive trajectory in market presence and product adoption, crucial for long-term growth.

Equity Position

A strong equity position reflects financial stability and provides a buffer against operational challenges, supporting long-term sustainability.

New Product Development

Advancements in product development like ATR-04 can enhance market competitiveness and drive future revenue through innovative solutions.

Negative Factors

Negative Cash Flow

Persistent negative cash flow limits operational flexibility and necessitates external funding, posing a risk to financial health and growth.

NYSE Compliance Risk

Non-compliance with NYSE requirements poses a risk of delisting, which could impact investor confidence and access to capital markets.

High Operating Losses

High operating losses indicate inefficiencies and financial strain, challenging the company's ability to achieve profitability and sustain operations.

Azitra Inc Business Overview & Revenue Model

Company Description

Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.

How the Company Makes Money

Azitra Inc generates revenue through a combination of product sales, licensing agreements, and collaborations with pharmaceutical companies. The primary revenue stream comes from the commercialization of its therapeutic products once they receive regulatory approval. In addition, Azitra may enter into partnerships with larger pharmaceutical companies for co-development and distribution of its products, which can provide upfront payments and milestone payments tied to clinical progress. The company also focuses on securing grants and funding for its research initiatives, which can supplement its income and support ongoing development efforts.

Azitra Inc Financial Statement Overview

Summary

Azitra Inc shows significant revenue growth, but persistent high losses and negative cash flows indicate operational inefficiencies and financial vulnerabilities. The balance sheet reflects improved equity, yet high liabilities and substantial cash burn remain critical challenges.

Income Statement

Azitra Inc reported significant revenue growth from $686,000 in 2023 to $7,500,000 in 2024, indicating a positive trajectory in revenue generation. However, the company suffers from extremely high net and operating losses, demonstrated by negative EBIT and EBITDA figures. The net profit margin remains negative due to substantial operational expenses surpassing revenue gains.

Balance Sheet

The balance sheet shows a strong equity position with stockholders' equity of $5,698,298,000 in 2024, reflecting a positive turnaround from negative equity in previous years. The debt-to-equity ratio is low, indicating prudent financial leverage. However, considerable liabilities could pose risks if revenue growth does not continue.

Cash Flow

Negative operating cash flows of -$10,183,740,000 in 2024 highlight cash constraints, limiting operational flexibility. Free cash flow remains deeply negative, though slight improvement is seen from the previous period. The lack of positive cash flows raises concerns about the company's ability to fund operations without external financing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	7.50M	686.00K	284.00K	110.00K
Gross Profit	-338.37K	7.50M	686.00K	284.00K	110.00K
EBITDA	-10.27M	-8.50M	-10.67M	-10.02M	-8.79M
Net Income	-11.11M	-8.97M	-11.28M	-10.68M	-8.94M
Balance Sheet
Total Assets	4.30M	7.36M	5.12M	7.17M	10.20M
Cash, Cash Equivalents and Short-Term Investments	1.40M	4.55M	1.80M	3.49M	8.04M
Total Debt	795.25K	555.51K	885.95K	7.73M	992.02K
Total Liabilities	2.02M	1.66M	2.20M	43.43M	35.97M
Stockholders Equity	2.28M	5.70M	2.91M	-36.26M	-25.77M
Cash Flow
Free Cash Flow	-11.10M	-10.56M	-7.68M	-8.69M	-8.72M
Operating Cash Flow	-10.92M	-10.18M	-7.36M	-8.35M	-8.07M
Investing Cash Flow	-214.58K	-379.25K	-318.26K	-336.76K	-652.27K
Financing Cash Flow	5.27M	13.32M	5.98M	4.13M	992.86K

Azitra Inc Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AZTR, the sentiment is Neutral. The current price of 0.3 is below the 20-day moving average (MA) of 0.30, below the 50-day MA of 0.36, and below the 200-day MA of 1.15, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 44.05 is Neutral, neither overbought nor oversold. The STOCH value of 49.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AZTR.

Azitra Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INM	44 Neutral	$3.51M	-0.18	-82.17%	―	-3.27%	51.83%
ENVB	42 Neutral	$4.18M	-0.04	-262.78%	―	―	79.45%
AZTR	41 Neutral	$3.26M	-0.06	-215.04%	―	-100.00%	93.82%
ONCO	33 Underperform	$2.67M	>-0.01	-263.57%	―	-34.58%	96.41%
OGEN	29 Underperform	$3.54M	-0.05	-168.95%	―	―	90.27%

Azitra Inc Corporate Events

Azitra Inc Compliance Plan Approved by NYSE American

Azitra, Inc. announced that NYSE American has approved its compliance plan to meet the exchange’s minimum stockholders’ equity requirement by April 1, 2027. While the company’s listing remains active during the plan period, failure to meet milestones or regain compliance by the deadline could lead to delisting proceedings, creating potential implications for operations and investor confidence.

The most recent analyst rating on (AZTR) stock is a Hold with a $0.37 price target. To see the full list of analyst forecasts on Azitra Inc stock, see the AZTR Stock Forecast page.

Azitra Inc Secures $1.5M in Private Placement

On November 24, 2025, Azitra, Inc. entered into a securities purchase agreement with an institutional investor, resulting in a private placement offering of approximately $1.5 million. The offering involved shares of common stock and warrants, with the proceeds intended for general corporate purposes. The agreement includes restrictions on issuing additional shares for 60 days and grants the investor participation rights in future financings. The placement was facilitated by Maxim Group LLC, and the company is required to file a registration statement for the resale of the securities.

The most recent analyst rating on (AZTR) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on Azitra Inc stock, see the AZTR Stock Forecast page.